April 19, 2019, Infectious Disease News 

The monoclonal antibody UB-421 “demonstrated unprecedented and sustained” virologic suppression in the absence of ART among people with HIV during a nonrandomized, open-label, phase 2 clinical study, according to findings published April 17 by The New England Journal of Medicine.

Read more.